Skip to main content
. 2022 Jun 24;82(16):2838–2847. doi: 10.1158/0008-5472.CAN-22-0554

Figure 4.

Figure 4. Derivation and performance of a BAL cfDNA genomic classifier for lung cancer diagnosis. A, BAL risk score based on 11 genomic features (Supplementary Table S9; Methods). Case–control status and relevant clinico-pathologic variables are indicated. NSCLC, non–small cell lung cancer. B, Individual performance of the top three features contributing to the BAL cfDNA classifier at the optimal cut point (Youden's value). Mean VAF% (green line), cancer driver genes (orange line), and number of mutations (blue line). C, Performance of the BAL cfDNA classifier using all 11 features at the optimal cut-off point (Supplementary Table S9). D, Sensitivity of the BAL genomic classifier and BAL cytology at a specificity of 100% for diagnosing lung cancer stratified by stage. Point estimates are represented by a circle and 95% confidence intervals by whiskers. Analysis based on 17 patients with cancer and 16 controls who had both cytology and BAL genomics scores available. E, Patient-level comparison of BAL cytology and BAL genomic classifier risk scores using a 100% specificity threshold. 17 patients with cancer and 16 non-cancer patients that had both cytology and a risk score assigned to them are arranged on the x-axis by stage and cancer status.

Derivation and performance of a BAL cfDNA genomic classifier for lung cancer diagnosis. A, BAL risk score based on 11 genomic features (Supplementary Table S9; see Materials and Methods). Case–control status and relevant clinicopathologic variables are indicated. NSCLC, non–small cell lung cancer. B, Individual performance of the top three features contributing to the BAL cfDNA classifier at the optimal cut point (Youden value). Mean VAF% (green line), cancer driver genes (orange line), and number of mutations (blue line). C, Performance of the BAL cfDNA classifier using all 11 features at the optimal cut-off point (Supplementary Table S9). D, Sensitivity of the BAL genomic classifier and BAL cytology at a specificity of 100% for diagnosing lung cancer stratified by stage. Point estimates are represented by a circle and 95% confidence intervals by whiskers. Analysis based on 17 patients with cancer and 16 controls who had both cytology and BAL genomics scores available. E, Patient-level comparison of BAL cytology and BAL genomic classifier risk scores using a 100% specificity threshold. Seventeen patients with cancer and 16 noncancer patients that had both cytology and a risk score assigned to them are arranged on the x-axis by stage and cancer status.